Related Experiment Video
Updated: Jun 6, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Validation of a Set of Clinical Criteria for the Diagnosis of Secondary Progressive Multiple Sclerosis
Alin Ciubotaru1,2, Daniel Alexa1,2, Cristina Grosu1,2
1Department of Neurology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania.
Abstract:
Background/Objectives: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by progressive impairment of neuronal transmission due to focal demyelination. The most common form is RRMS (relapsing-remitting multiple sclerosis), which, under the influence of certain factors, can progress to SPMS (secondary progressive multiple sclerosis). Our study aimed to validate the criteria proposed by a working group of the Romanian Society of Neurology versus the criteria proposed by a group of experts from Spain, Karolinska, and Croatia concerning the progression from RRMS to SPMS. Methods: This was done by gathering epidemiological data (age, gender) and by applying clinical tests such as the 9HPT (9-hole peg test), 25FWT (25-foot walk test), and EDSS (expanded disability status scale) tests and the SDMT test (symbol digit modalities test). The present research is a cohort study that included a number of 120 patients diagnosed with MS according to the McDonald Diagnostic Criteria 2017. The study was carried out between January 2023 and April 2024, including patients hospitalized in the Neurology Clinic of the Clinical Rehabilitation Hospital from Iasi, Romania. The data were collected at baseline (T0) and at a 12-month interval (T1). Results: The statistical analysis was conducted using Kaiser-Meyer-Olkin analysis, which indicated a value of 0.683, thus validating the clinical tests used. The correlation matrix and the linear regression for all the tests showed highly significant statistical results. Furthermore, the ROC curve analysis of the criteria suggested by the working group of the Romanian Society of Neurology demonstrated that the EDSS, 9HPT, and 25FWT are highly sensitive in diagnosing SPMS, an opinion that is shared with the Spanish experts, but not with the Karolinska expert panel. Using the criteria given by the Croatian expert group in the ROC curve analysis showed that only the EDSS was strongly significant for the progression to the SPMS phase. Conclusions: In conclusion, all clinical methods used demonstrated that they are valid and can contribute to identifying patients with an increased risk of progression. The model proposed by the Romanian Society of Neurology working group is similar to other countries' expert opinions and can be used to detect the risk of disease progression and establish a more tailored therapeutic management of SPMS.
Insights
This study validates clinical tests for tracking multiple sclerosis (MS) progression from relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS). The Romanian Society of Neurology
Area of Science:
- Neurology
- Clinical Research
- Epidemiology
Background:
- Multiple sclerosis (MS) is a chronic CNS inflammatory disease with demyelination.
- Relapsing-remitting MS (RRMS) can progress to secondary progressive MS (SPMS).
- Validating criteria for RRMS to SPMS progression is crucial for patient management.
Purpose of the Study:
- To validate criteria for RRMS to SPMS progression proposed by Romanian experts against international criteria.
- To assess the efficacy of clinical tests in identifying MS progression.
Main Methods:
- A cohort study of 120 MS patients diagnosed via McDonald Criteria 2017.
- Data collection included epidemiological factors and clinical tests: 9-hole peg test (9HPT), 25-foot walk test (25FWT), expanded disability status scale (EDSS), and symbol digit modalities test (SDMT).
- Data analyzed at baseline (T0) and 12-month follow-up (T1) using statistical methods including ROC curve analysis.
Main Results:
- Kaiser-Meyer-Olkin analysis (0.683) validated the clinical tests used.
- ROC analysis showed EDSS, 9HPT, and 25FWT are highly sensitive for diagnosing SPMS, aligning with Spanish experts but not Karolinska.
- Croatian expert criteria indicated only EDSS was significant for SPMS progression.
Conclusions:
- All clinical methods are valid for identifying patients at risk of MS progression.
- The Romanian Society of Neurology's model aligns with international expert opinions for detecting progression risk.
- This validation supports tailored therapeutic management for SPMS.

